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Abstract
Modern concepts of osteoarthritis (OA) have been forever
changed by modern imaging phenotypes demonstrating
complex and multi-tissue pathologies involving cartilage,
subchondral bone and (increasingly recognized)
inflammation of the synovium. The synovium may show
significant changes, even before visible cartilage
degeneration has occurred, with infiltration of
mononuclear cells, thickening of the synovial lining layer
and production of inflammatory cytokines. The
combination of sensitive imaging modalities and tissue
examination has confirmed a high prevalence of synovial
inflammation in all stages of OA, with a number of
studies demonstrating that synovitis is related to pain,
poor function and may even be an independent driver of
radiographic OA onset and structural progression.
Treating key aspects of synovial inflammation therefore
holds great promise for analgesia and also for structure
modification. This article will review current knowledge
on the prevalence of synovitis in OA and its role in
symptoms and structural progression, and explore
lessons learnt from targeting synovitis therapeutically.
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Background
Osteoarthritis (OA) is the most common form of
arthritis and a major cause of joint pain and disabil-
ity. We live longer than our ancestors and, for the
first time in history, people aged 65 years and older
will outnumber children younger than 5 years, and
the number of people aged 60 years and above is ex-
pected to double by 2050 and more than triple by
2100 [1]. Being primarily related to ageing, the preva-
lence of OA will steadily increase and is expected to
be the single greatest cause of disability in the general
population by 2030 [2]. This will not only affect indi-
viduals’ quality of life but also account for substantial
burden on health care systems globally. Yet current
analgesic therapies are limited in efficacy and by sig-
nificant toxicity and there are no licensed disease-
modifying drugs.
In the early 1980s, histopathological analysis of OA
synovium demonstrated abundant inflammation in the
majority of OA patients [3]. While traditionally con-
sidered primarily a disease of hyaline cartilage with
associated bone involvement, caused by overload or
overuse, the pathophysiology of OA development is
now appreciated to be more complex. Mounting
evidence suggests that synovitis and the resultant pro-
inflammatory mediators are important in the
pathogenesis of OA with effects on articular cartilage
[4, 5]. Modern imaging modalities such as magnetic
resonance imaging (MRI) and ultrasound have con-
firmed a high prevalence of ‘macroscopic’ inflamma-
tion and have supported the role of synovitis as an
active component of the OA process, associated with
both pain and structural progression (Table 1).
In this narrative review, we aim to summarize
current knowledge on the role of synovitis in OA with
emphasis on recent research on pathophysiology and
epidemiology, and the lessons learned from recent tri-
als targeting synovial inflammatory mediators. We se-
lected papers in English with relevance to peripheral
joint OA and attempted to include updates on a var-
iety of OA anatomical sites, although much of the lit-
erature focus remains on knees. Although we have
focused on synovitis, it is important to note that pro-
inflammatory mediators may also arise from multiple
OA joint structures including the infrapatellar fat pad.
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Table 1 Evidence for the role of synovitis
Level of evidence Observation References
Clinical Effusion, joint swelling or palpable synovitis Thomas et al. [2], Sellam et al. [5], de Lange-Brokaar [39]
Sudden increase in pain
Night pain and morning stiffness
Histological Synovial hypertrophy and hyperplasia Goldenberg et al. [3], Prieto-Potin et al. [8], Klein-Wieringa et al. [9],
Deligne et al. [10], de Lange-Brokaar et al. [11], Goldring [13]
Infiltration of mononuclear cells (monocytes/macrophages,
activated B cells and T cells)
Adaptive immune T-cell and B-cell responses to fragments
of extracellular matrix
Macrophages cluster and form multinucleated giant cells
for improved phagocytosis
Increased angiogenesis
Synovitis close to degenerative cartilage
Molecular Production and/or release of pro-inflammatory cyto-
kines (TNF, IL-1β, IL-6, IL-8, IL-15, IL-17, IL-18, IL-21)
Sokolove and Lepus [12], Wojdasiewicz et al. [16], Larsson et al. [61],
Pustjens et al. [18]
Increased production of PGE2 and nitric oxide
Increased expression of adhesion molecules
(ICAM-1, VCAM-1) in the synovium
Increased activity of MMPs (MMP-1, MMP-3, MMP-9,
MMP-13) and ADAMTS
Production of adipokines (visfatin, leptin, adiponectin)
Release of EGF and VEGF
Involvement of macrophages in osteophyte formation
via BMPs
Insufficient release of anti-inflammatory cytokines
(IL-4, IL-10, IL-13, IL-1Ra)
Release of pro-inflammatory and pain neurotransmitters
(substance P, NGF)
Imaging Gadolinium-enhanced synovium and increased synovial
volume detected by MRI
de Lange-Brokaar et al. [21], Loeuille et al. [22], Sarmanova et al. [27],
Mathiessen et al. [29], Haugen et al. [26], Kortekaas et al. [30], Yusuf et al.
[35], de Lange-Brokaar et al. [39], Felson et al. [41], Damman et al. [49]
MRI correlates with histological observations and joint
volume by arthrocentesis
High prevalence of synovial hypertrophy and effusion
using ultrasound
Association between MRI-detected and ultrasound-
detected synovitis and clinical symptoms of synovitis
MRI-detected and ultrasound-detected synovitis predicts
incident radiographic OA, progression and cartilage
degradation
Interventions High dose of IA corticosteroid injection may have short-term
effects on clinical symptoms and synovial tissue volume
Zhang et al. [53], O’Neill et al. [50], Keen et al. [56], Wenham et al.
[58], Wenham et al. [59]
Methotrexate may have an analgesic effect
Biological response modifiers have potentially structural-
modifying effects
Adapted from [5] with permission from Macmillan Publishers Ltd
ADAMTS a disintegrin and metalloproteinase with thrombospondin motifs, BMP bone morphogenetic protein, EGF endothelial growth factor, IA intraarticular,
ICAM-1 intercellular adhesion molecule 1, IL interleukin, IL-1Ra interleukin 1 receptor antagonist, MMP matrix metalloproteinase, MRI magnetic resonance imaging,
NGF nerve growth factor, OA osteoarthritis, PGE2 prostaglandin E2, TNF tumour necrosis factor, VCAM-1 vascular cell adhesion molecule 1, VEGF vascular
endothelial growth factor
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Synovial pathophysiology
Normal synovium
The synovium is a specialized connective tissue that lines
diarthrodial joints, surrounds tendons and forms the lining
of bursae and fat pads. In synovial joints, the synovium
seals the synovial cavity and fluid from surrounding tissues.
The synovium is responsible for the maintenance of syn-
ovial fluid volume and composition, mainly by producing
lubricin and hyaluronic acid. Through the synovial fluid,
the synovium also aids in chondrocyte nutrition (together
with subchondral bone), as articular cartilage has no intrin-
sic vascular or lymphatic supply [6].
The normal synovium has two layers. The outer layer, or
subintima, is up to 5 mm thick and consists of multiple
types of connective tissues: fibrous (dense collagenous type),
adipose (found mainly in fat pads) or areolar (loose collage-
nous type). This layer is rich in type I collagen and micro-
vascular blood supply, accompanied by lymphatic vessels
and nerve fibres, but is relatively acellular [7]. The inner
layer, or intima, lies next to the joint cavity and consists of a
layer of 1–4 cells, only 20–40 μm thick. These synoviocytes
have been identified by immunohistochemical and cyto-
chemical methods as macrophages and fibroblasts; the latter
is the dominant cell population in healthy synovium [7].
Changes in OA synovium
The histological pattern of synovium in OA patients is
characterized by synovial lining hyperplasia, sublining
fibrosis and stromal vascularization [8]. There is an
abundant influx of leukocytes from the vascular compart-
ment in response to cytokines and cell adhesion molecules
[6], and several studies have shown macrophages and T-
cell lymphocytes to be the most predominant immune
cells in OA synovium, whereas mast cells, B cells and
plasma cells are also found but to a lesser extent [9–11].
Macrophage infiltration in the synovium is common in
both OA and RA [8]. These macrophages can cluster and
form multinucleated giant cells (MGCs) for improved
phagocytosis, and are increased in similar numbers in in-
flamed OA and RA synovia compared with non-inflamed
OA and post-mortem controls [8]. However, OA and RA
demonstrate slightly different subgroups of MGCs, sug-
gesting different drivers for these clusters, such as more
cartilage debris in OA.
Much of the innate immune activation and cytokine
production in the OA joint is attributed to synovial mac-
rophages, but other cells including synoviocytes and chon-
drocytes also play a role [12]. The underlying mechanisms
are complex and beyond the scope of this review. In short,
molecules from degraded hyaline cartilage released into
the synovial cavity are likely to initiate synovial inflamma-
tion in OA (Fig. 1). Early in knee OA, damage to the me-
niscus may also release tissue debris, although molecules
released from subchondral bone may also play a role.
Synoviocytes react by producing pro-inflammatory media-
tors, which in turn attract immune cells, increase angio-
genesis and induce a phenotypic shift in chondrocytes
[13]. A vicious cycle follows, as chondrocytes produce
Fig. 1 Involvement of the synovium in OA pathophysiology. Products of cartilage breakdown released into the synovial fluid are phagocytosed by
synovial cells, amplifying synovial inflammation. In turn, activated synovial cells in the inflamed synovium produce catabolic and pro-
inflammatory mediators that lead to excess production of the proteolytic enzymes responsible for cartilage breakdown, creating a positive
feedback loop. The inflammatory response is amplified by activated synovial T cells, B cells and infiltrating macrophages. To counteract
this inflammatory response, the synovium and cartilage may produce anti-inflammatory cytokines. In addition to these effects on cartilage
inflammation and breakdown, the inflamed synovium contributes to the formation of osteophytes via BMPs. ADAMTS a disintegrin and
metalloproteinase with thrombospondin motifs, BMP bone morphogenetic protein, CXCL13 CXC-chemokine ligand 13, EGF endothelial
growth factor, IL interleukin, IL-1Ra IL-1 receptor antagonist, LTB4, leukotriene B4, MMP matrix metalloproteinase, NAMPT nicotinamide
phosphoribosyl transferase (visfatin), NO nitric oxide, OA osteoarthritis, PGE2 prostaglandin E2, TiMP tissue inhibitor of metalloproteinase,
TNF tumour necrosis factor, VCAM-1, vascular cell adhesion molecule 1, VEGF vascular endothelial growth factor (Reprinted from [5] with
permission from Macmillan Publishers Ltd)
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additional cytokines and proteolytic enzymes that eventu-
ally increase cartilage degradation and induce further
synovial inflammation [4].
The processes driving inflammation in OA are com-
plex. Given that OA is age related, immunosenescence
may play a role in the immune response to tissue dam-
age. A recent report analysed immune cell composition
of the blood of OA patients and found compromised
immune function of T cells and B cells beyond what
appeared directly related to ageing, and this could reflect
both inflammation and autoreactivity [14]. Also, trauma
can trigger release of local inflammatory mediators, and
there is increasing evidence that metabolic syndrome
and obesity increase systemic low-grade inflammatory
mediators which may synergize with other inflammatory
mechanisms in OA [15].
The role of cytokines
Wojdasiewicz et al. [16] recently described in detail the
mediating cytokines and their signalling pathways that
are up-regulated in OA and most often have catabolic
(i.e. degrading) effects, including interleukin-1 beta
(IL-1β), tumour necrosis factor (TNF) alpha, IL-6, IL-15,
IL-17 and IL-18. IL-1β and TNF-α have been the most
extensively studied cytokines. They are elevated in OA
synovial fluid, synovial membrane, cartilage and subchon-
dral bone and, in the course of OA, have synergistic
effects on signalling pathways that increase inflammation
and cartilage degradation [16]. Despite these known
actions, anti-TNF treatment has not provided symptom-
atic benefits in OA randomized trials, although it has
reduced structural progression in individual joints with
high degrees of inflammation, whereas IL-1β inhibition
has so far been disappointing in terms of symptom and
structural benefits.
Another group of ‘haematopoietic’ cytokines, or colony-
stimulating factors (CSFs), is known to activate and
mature myeloid cells both systemically and locally [17],
and there is an increased interest in targeting these CSFs
in inflammatory and autoimmune diseases. During an
inflammatory response, they act more distinctly and re-
stricted on cell receptors than other cytokines, causing
increased cell numbers of selected myeloid populations
and enhancing their survival or modifying tissue destina-
tions. Preliminary data show beneficial effects of anti-CSF
therapies in OA models, and a phase II trial in inflamma-
tory hand OA has been initiated [17].
Some cytokines (such as IL-4, IL-10 and IL-13) have
anti-inflammatory and sometimes anabolic effects, and
may modulate an inflammatory response and slow pro-
gression of OA [16]. In a healthy joint, the balance be-
tween anabolic and catabolic cytokines contributes to
stable turnover of cartilage, whereas an imbalance is found
in OA. Although the literature is limited, there is emer-
ging evidence that an up-regulation of these cytokines,
either individually or combined, may induce cartilage
repair in OA. A novel fusion protein of IL-4 and IL-10 has
induced both structural repair and reduced inflammation
ex vivo, and inhibited pain in animal models of OA [18].
Epidemiology
There is extensive evidence for synovitis being a common
feature in OA. Tissue histology and immunohistochemis-
try have been used to identify synovitis and modern im-
aging techniques such as MRI and ultrasound are capable
of visualizing aspects of synovitis, such as increased vascu-
lar flow, hypertrophic synovium and effusion. In addition,
semi-quantitative scoring systems have enabled improved
understanding of synovitis in OA pathogenesis and pro-
gression [19]. The prevalence of synovitis in OA joints
depends on the diagnostic technique applied, on patient/
cohort selection and on OA structural severity. However,
prevalence studies do not often capture non-steroidal
anti-inflammatory drug (NSAID) use, and it is possible
that the anti-inflammatory action of these agents could
lead to an underestimation of synovitis.
Microscopic assessment of synovitis
OA synovial tissue typically displays a mild to moderate
degree of inflammation on standard histological staining
[20]. In smaller histological studies, the prevalence of in-
flamed synovium ranges greatly from approximately half to
nearly all tissue samples depending on patient pre-selection
and OA severity [11]. When comparing microscopic syn-
ovial changes in early and late OA, the literature has shown
conflicting results [11], probably due to different definitions
of ‘early’ and ‘late’ OA.
Macroscopic assessment of synovitis
At the ‘macroscopic’ level, MRI provides valuable insights
into synovitis and can visualize synovial hypertrophy, syn-
ovial fluid volume and level of synovial enhancement after
intravenous injection of a contrast agent (Fig. 2). In terms
of validity, MRI inflammation measures correlate well
with histological inflammation and with effusion volume
on arthrocentesis [21, 22]. In over a thousand knee OA
patients, non-contrast-enhanced (non-CE)-MRI synovitis
was present in 60% and effusion in 66% [23]. On CE-MRI,
synovitis has been strongly correlated with radiographic
OA severity and was reported in 74% of 404 patients hav-
ing all grades of knee OA [24], and in 95% of 125 patients
with mainly moderate to severe radiographic OA [25].
With respect to meniscal damage, only severe lesions have
shown borderline association with synovitis [24]. MRI
scans of hand OA patients have demonstrated synovitis in
a median (interquartile range) 6 (4–7) interphalangeal
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joints of the dominant hand, with moderate to severe
synovitis (grade 2–3) being infrequent [26].
Although ultrasound cannot assess cartilage deep in the
joint or intra-bone lesions, it is well suited to assess in-
flammatory changes. A large meta-analysis of ultrasound-
detected synovial changes found that people with knee
OA or knee pain had high prevalence of effusion, synovial
hypertrophy and power Doppler signals (ranging from 33
to 52% of the knees), and that these measures correlated
well with histological findings [27]. A large multicentre
study using ultrasound in 600 people with symptomatic
knee OA demonstrated synovial inflammation or effusion
in 46% of the population, despite using a strict definition
of synovial hypertrophy [28]. In two large hand OA co-
horts, nearly all patients (94% and 96%) had evidence of
sonographic synovitis by grey scale in at least one finger
joint [29, 30] and by power Doppler signals in 42% of the
patients [29]. At the joint level, 28.7% of 1078 finger joints
with Kellgren & Lawrence grade ≥ 2 demonstrated syn-
ovial effusion and/or hypertrophy by ultrasound [29].
Is inflammatory OA a separate subtype?
With MRI and US studies demonstrating a high frequency
of synovitis, it remains unclear whether inflammatory OA
is a distinct subtype or just part of the spectrum of OA
pathology severity. The group with more severe inflamma-
tion can be identified with imaging and serum biomarkers
(such as the matrix metalloproteinase-dependent degrad-
ation of C-reactive protein (CRPM), connective tissue type
I collagen turnover (C1M) and matrix metalloproteinase 3
(MMP-3)) [15]. To add further complexity, the expression
of a given phenotype also depends on person-specific
factors such as local muscle strength and obesity. A study
followed two selected groups of knee OA patients for
Fig. 2 a Sagittal fat-suppressed proton density-weighted image (non-CE-MRI) shows hyperintensity in the intercondylar (arrow) region of Hoffa’s fat pad.
This signal alteration is used as a surrogate marker for synovitis on non-CE-MRI. There is a discrete subchondral bone marrow alteration in the femur
(arrowhead) corresponding to the site of the anterior cruciate ligament (ACL) insertion. b In contrast, sagittal fat-suppressed T1-weighted contrast-
enhanced MRI (CE-MRI) shows no intercondylar synovitis, but reveals infrapatellar synovitis and synovitis adjacent to the tibial ACL insertion (arrows) not
seen on non-CE-MRI, as well as bone marrow edema (arrowhead). c Axial non-CE-MRI shows a fluid-equivalent signal within the joint cavity suggestive of
joint effusion in the peripatellar recesses (arrows) and posteriorly (arrowhead). d Axial CE-MRI shows marked synovitis anteriorly (arrows) and true effusion
only depicted posteriorly as hypointensity adjacent to the synovial lining (arrowhead). Reprinted from [62] with permission from Elsevier
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4 years: one with metabolic syndrome and one lean group
with frequent physical activity [31]. These groups differed
significantly in the MRI expression of joint pathology, in
which Hoffa synovitis was more prevalent in the active
lean group, and prepatellar bursa signal, osteophyte scores
and cartilage damage scores were higher and more preva-
lent in the metabolic syndrome group [31]. Inflammatory
OA is a term often applied to a subset of hand OA with a
greater degree of synovial inflammation and associated
with radiographic erosive disease [32].
Synovitis and symptoms
With different approaches employed in the detection and
characterization of synovitis (such as histologic or imaging
assessment), overall the literature provides consistent evi-
dence of an association between synovial inflammation
and OA symptoms, although the strengths of such associ-
ations vary and often studies do not examine all involved
OA pathologies to explore which tissues are independ-
ently contributing to pain. Synovial inflammation in-
creases the responsiveness of peripheral nociceptive
neurons, leading to heightened pain sensitivity, and
thereby contributes to increased pain experience [23].
Local immune cells and cytokines may modulate this
altered pain perception, as demonstrated in knee OA
patients when synovial CD4+ T cells were associated with
VAS pain (adjusted for age, sex and BMI) [9]. No associ-
ation was found for other immune cells. Furthermore,
these CD4+ T cells secreted TNF-α and IL-6, which have
been shown to directly affect sensory fibre function.
Before considering structure–pain relationships, it is
worth considering the many differences between studies.
Especially in large joints such as the knees, synovitis is
found in a patchy distribution, and distinct patterns of
synovitis may have different relationships to pain [33, 34].
Also, just as there are differences in how we detect syno-
vitis, there are differences in how we measure ‘pain’. In
some studies, associations may be with VAS global pain
intensity scores, in other studies with summed WOMAC
pain scores. We still need to understand more about
individual symptoms and their relationship to particular
structural pathologies. Importantly, pain is a complex
experience in which changes may be attributed to several
peripheral nociceptive factors other than inflammation, as
well as central factors.
Cross-sectional data
A systematic review from 2011 found an increased risk of
MRI-detected synovitis and effusion in patients with
symptomatic knee OA [35], but none of the included
papers employed CE-MRI, without which effusion and
synovitis cannot be readily differentiated. There are, how-
ever, emerging data for an even stronger association with
pain severity when contrast enhancement is used [36].
Several cross-sectional studies on hand OA have shown
similar associations between sonographic or MRI-detected
synovitis and concurrent pain. A hand OA cohort applying
ultrasound found inflammatory features (i.e. grey-scale syn-
ovial effusion or hypertrophy and power Doppler signals)
to be significantly and dose-dependently associated with
pain upon palpation and with the Australian/Canadian
Osteoarthritis Hand Index (AUSCAN) pain and stiffness
subscales and the Short Form (SF)-36 [30]. These results
were replicated with MRI in another cohort [26],
suggesting that synovial inflammation can cause pain also
in hand OA.
Longitudinal data
The effects of synovitis on longitudinal measurements of
pain are more complex to measure and results are ambigu-
ous. Most studies have been performed on knee OA co-
horts with 2–5 years of follow-up, often assessing VAS
pain, WOMAC, KOOS or ICOAP. Some studies find an
improvement in pain when some (but not all) aspects of
synovial inflammation diminish [37] and a worsening of
pain with increased inflammation over time [38], whereas
others do not replicate these associations [39]. In hand OA
patients, MRI-detected synovitis has been found to predict
incident joint tenderness but not AUSCAN pain [40].
Synovitis and structural progression
Incident OA
The effect of synovitis on OA is confounded by concur-
rent pathologies, raising an important question: does
synovitis have an independent effect on OA progression?
Felson et al. [41] recently examined the risk for incident
radiographic knee OA after adjusting for structural path-
ology known to cause synovitis. The authors compared
239 cases and 731 control knees in the MOST cohort and
found that cartilage lesions, meniscal damage, synovitis
and BMLs were all risk factors for OA. Furthermore, when
adjusting for confounding pathologies, synovitis remained
associated with incident radiographic OA when the total
synovitis score was 3 or higher on a 0–9 scale (OR 1.6,
95% CI 1.2–2.1). Another paper from the same cohort
showed that knees without OA (i.e. having neither MRI-
defined cartilage damage nor tibiofemoral radiographic
OA) had a significant increased risk of cartilage loss when-
ever effusion synovitis was present (OR 2.7, 95% CI
1.4–5.1), independent of confounders for inflammation
and cartilage loss [42]. These results suggest that synovitis
effusion assessed on non-CE-MRI is an independent
predictor of incident radiographic OA.
A series of recent papers from the OA Initiative (OAI)
also support the importance of synovitis prior to incident
radiographic OA. Atukorala et al. [43] performed nested
case–control analyses on 133 knee joints that developed
radiographic knee OA and an equal number of joints that
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did not develop knee OA. The authors found effusion
synovitis and Hoffa synovitis 1 year prior to diagnosis to
be significantly associated with subsequent OA develop-
ment (OR 3.23, 95% CI 1.72–6.06 and OR 2.40, 1.43–
4.04). A similar design was applied by Roemer et al. [44],
who looked at repeated MRI scans up to 4 years prior to
evident radiographic knee OA. They found that presence
of Hoffa synovitis, effusion synovitis, medial BMLs and
medial meniscal damage increased the risk of OA 2 years
prior to incident radiographic OA, and that the number of
features present increased the risk more than the presence
of any single feature. More studies examining the inci-
dence of the earliest detected MRI changes of OA will be
required to understand more definitely the role of syno-
vitis in the early stages of OA.
Progression of OA
There is strong evidence that synovitis is associated with
further worsening of OA structure. Longitudinal analyses
of 531 knee OA patients demonstrated that ultrasound-
detected effusion predicted pain, radiographic progression
and also joint replacement [45]. There are also cohorts
reporting higher risk of radiographic progression and car-
tilage deterioration over 2 years in knee joints with in-
creased MRI synovitis score over time than those with a
decrease in synovitis [39, 46].
Studies of hand OA patients report similar associations.
Using ultrasound, Mathiessen et al. [29] found grey-scale
synovitis and power Doppler signals at baseline to strongly
predict radiographic progression after 5 years, and even
more so when inflammation persisted [47]. Similar results
were found in two cohorts using MRI on hand OA
patients, as gadolinium-enhanced synovitis was associated
with both onset and progression of radiographic hand
OA, including development of erosions [48, 49]. The total
amount of synovial inflammation also increased the risk of
progression [49].
Treating OA synovitis—what have we learnt?
The data presented strongly suggest that synovitis is
involved in OA symptoms and progression, and therefore
represents an important target for therapeutic
intervention.
While symptoms are the usual primary outcome of an
analgesic OA trial, imaging or serum biomarkers of
synovial inflammation may provide evidence for proof of
mechanism [15]. Synovial tissue volume was used for
this purpose in a recent open-label study of 120 patients
with knee OA receiving intra-articular (IA) steroid injec-
tion with subsequent reduction in CE-MRI synovial
volume that correlated with improvement in knee pain
[50]. Dynamic CE-MRI-derived measurements of syn-
ovial enhancement, where images are acquired every few
seconds after contrast injection, were shown to be even
more sensitive to the response of treatment and more
strongly associated with changes in pain than synovial
tissue volume [51, 52].
Existing therapies
Part of the evidence to support therapeutic targeting of
inflammation in OA is that the two pharmacological
therapies with consistently good effect sizes in relieving
OA pain are NSAIDs and IA corticosteroid injections
[53]; both have anti-inflammatory mechanisms of action.
Further support for the concept of treating inflammation
is that the analgesic benefits from IA steroids also seem
dose dependent. In a hip OA study where 120 patients
received either 40 or 80 mg of IA corticosteroids, both
doses had a beneficial effect at week 6 (in terms of pain,
stiffness and disability), while the 80 mg dose demonstrated
a statistically significant benefit at week 12 [54]. This stands
in contrast to low-dose oral prednisolone (5 mg) which had
no analgesic effect on 70 hand OA patients in a short-term
(4 weeks) randomized controlled trial [55]. Intramuscular
depot corticosteroid demonstrated somewhat better results
with significant short-term effects on knee pain [56],
although no statistically significant reduction in ultrasound-
detected synovial inflammation was found [56]. A prelimin-
ary report of a novel slow-release, microsphere formulation
of triamcinolone in a large OA knee randomized controlled
trial demonstrated important analgesic benefits to 13 weeks,
offering hope of long-lasting IA steroid therapy [57].
Potential therapies
Methotrexate (MTX) has an anti-inflammatory effect by
suppressing the inflammatory functions of neutrophils,
macrophages and monocytes, dendritic cells and lympho-
cytes through adenosine release, and thereby reducing se-
cretion of inflammatory cytokines, including TNF-α and
IL-6. A recent open-label pilot study of 30 patients with
knee OA who took a MTX dose of 15–20 mg/week for
6 months suggested an analgesic benefit, with 43% achiev-
ing the Osteoarthritis Research Society International
(OARSI) responder criteria [58]. A subsequent random-
ized controlled trial is underway.
A recent review has summarized the role of biologic
therapies that modify inflammatory components,
including anti-TNF agents, growth factors and IL-1 an-
tagonists, and their reported effects in OA trials [59].
Anti-TNF agents have to date had minimal effects on
symptoms, although the trial designs are heterogeneous
and there may be a possible structural-modifying effect
in joints with the most inflammation [60]. Also, there
are emerging and promising data on anti-inflammatory
cytokines such as IL-4 and IL-10, as well as anti-CSF
therapies, as described earlier.
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Conclusions
Even allowing for discrepancies between studies, synovitis
is a common finding in OA joints and has been associated
with clinical symptoms; our current best analgesic therapies
work by anti-inflammatory mechanisms supporting the
benefits of targeting inflammation to reduce pain. Overall
evidence suggests that synovial inflammation is associated
with progressive joint failure at least in a subgroup of pa-
tients, and thus some OA patients may benefit structurally
from an anti-inflammatory intervention. The failure to
identify and select subgroups of patients who will benefit
most may be the reason why treatment trials targeting
inflammation have failed to show convincing and long-
lasting effects on structure modification and symptoms, but
advances in imaging and soluble biomarkers may well pro-
vide the tools for appropriate stratification and understand-
ing the mechanism of action. More work is required on the
molecular pathways initiating and perpetuating synovial
inflammation, because dissection of these pathways will
provide novel therapeutic opportunities.
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